These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 11802585

  • 21. Postlicensure epidemiology of childhood vaccination: the Danish experience.
    Hviid A.
    Expert Rev Vaccines; 2006 Oct; 5(5):641-9. PubMed ID: 17181438
    [Abstract] [Full Text] [Related]

  • 22. Rotavirus vaccination and intussusception: can we decrease temporally associated background cases of intussusception by restricting the vaccination schedule?
    Tai JH, Curns AT, Parashar UD, Bresee JS, Glass RI.
    Pediatrics; 2006 Aug; 118(2):e258-64. PubMed ID: 16882770
    [Abstract] [Full Text] [Related]

  • 23. Safety monitoring in vaccine development and immunization.
    Lee CJ, Lee LH, Lu CH, Huang YJ, Chu ML.
    Acta Paediatr Taiwan; 2006 Aug; 47(1):7-13. PubMed ID: 17016963
    [Abstract] [Full Text] [Related]

  • 24. Intussusception and rotavirus vaccination: a review of the available evidence.
    Patel MM, Haber P, Baggs J, Zuber P, Bines JE, Parashar UD.
    Expert Rev Vaccines; 2009 Nov; 8(11):1555-64. PubMed ID: 19863248
    [Abstract] [Full Text] [Related]

  • 25. Live attenuated measles and mumps viral strain-containing vaccines and hearing loss: Vaccine Adverse Event Reporting System (VAERS), United States, 1990--2003.
    Asatryan A, Pool V, Chen RT, Kohl KS, Davis RL, Iskander JK, VAERS team.
    Vaccine; 2008 Feb 26; 26(9):1166-72. PubMed ID: 18255204
    [Abstract] [Full Text] [Related]

  • 26. Vaccine adverse events in a safety net healthcare system and a managed care organization.
    Narwaney KJ, Breslin K, Ross CA, Shoup JA, Wain KF, Weintraub ES, McNeil MM, Hambidge SJ.
    Vaccine; 2017 Mar 01; 35(9):1335-1340. PubMed ID: 28185740
    [Abstract] [Full Text] [Related]

  • 27. Surveillance of measles-mumps-rubella vaccine-associated aseptic meningitis in Germany.
    Schlipköter U, Mühlberger N, von Kries R, Weil J.
    Infection; 2002 Dec 01; 30(6):351-5. PubMed ID: 12478324
    [Abstract] [Full Text] [Related]

  • 28. Elective termination of pregnancy after vaccination reported to the Vaccine Adverse Event Reporting System (VAERS): 1990-2006.
    Chang S, Ball R, Braun MM.
    Vaccine; 2008 May 02; 26(19):2428-32. PubMed ID: 18406499
    [Abstract] [Full Text] [Related]

  • 29. Assessment of postlicensure safety of rotavirus vaccines, with emphasis on intussusception.
    Bines JE, Patel M, Parashar U.
    J Infect Dis; 2009 Nov 01; 200 Suppl 1():S282-90. PubMed ID: 19817611
    [Abstract] [Full Text] [Related]

  • 30. Broadening the age restriction for initiating rotavirus vaccination in regions with high rotavirus mortality: benefits of mortality reduction versus risk of fatal intussusception.
    Patel MM, Clark AD, Glass RI, Greenberg H, Tate J, Santosham M, Sanderson CF, Steele D, Cortese M, Parashar UD.
    Vaccine; 2009 May 14; 27(22):2916-22. PubMed ID: 19428901
    [Abstract] [Full Text] [Related]

  • 31. Safety considerations for new vaccine development.
    Ellenberg SS.
    Pharmacoepidemiol Drug Saf; 2001 May 14; 10(5):411-5. PubMed ID: 11802587
    [Abstract] [Full Text] [Related]

  • 32. Vaccine adverse events: separating myth from reality.
    Kimmel SR.
    Am Fam Physician; 2002 Dec 01; 66(11):2113-20. PubMed ID: 12484693
    [Abstract] [Full Text] [Related]

  • 33. More on RotaShield and intussusception: the role of age at the time of vaccination.
    Simonsen L, Viboud C, Elixhauser A, Taylor RJ, Kapikian AZ.
    J Infect Dis; 2005 Sep 01; 192 Suppl 1():S36-43. PubMed ID: 16088803
    [Abstract] [Full Text] [Related]

  • 34. The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety.
    McNeil MM, Gee J, Weintraub ES, Belongia EA, Lee GM, Glanz JM, Nordin JD, Klein NP, Baxter R, Naleway AL, Jackson LA, Omer SB, Jacobsen SJ, DeStefano F.
    Vaccine; 2014 Sep 22; 32(42):5390-8. PubMed ID: 25108215
    [Abstract] [Full Text] [Related]

  • 35. Projected cost-effectiveness of rotavirus vaccination for children in Asia.
    Podewils LJ, Antil L, Hummelman E, Bresee J, Parashar UD, Rheingans R.
    J Infect Dis; 2005 Sep 01; 192 Suppl 1():S133-45. PubMed ID: 16088797
    [Abstract] [Full Text] [Related]

  • 36. Combination vaccines: postlicensure safety evaluation.
    Chen RT, Pool V, Takahashi H, Weniger BG, Patel B.
    Clin Infect Dis; 2001 Dec 15; 33 Suppl 4():S327-33. PubMed ID: 11709768
    [Abstract] [Full Text] [Related]

  • 37. Near real-time vaccine safety surveillance with partially accrued data.
    Greene SK, Kulldorff M, Yin R, Yih WK, Lieu TA, Weintraub ES, Lee GM.
    Pharmacoepidemiol Drug Saf; 2011 Jun 15; 20(6):583-90. PubMed ID: 21538670
    [Abstract] [Full Text] [Related]

  • 38. Cost-effectiveness and potential impact of rotavirus vaccination in the United States.
    Widdowson MA, Meltzer MI, Zhang X, Bresee JS, Parashar UD, Glass RI.
    Pediatrics; 2007 Apr 15; 119(4):684-97. PubMed ID: 17403839
    [Abstract] [Full Text] [Related]

  • 39. Monitoring vaccine safety using the Vaccine Safety Datalink: utilizing immunization registries for pandemic influenza.
    McCarthy NL, Gee J, Weintraub E, Donahue JG, Nordin JD, Daley MF, Naleway A, Henninger M, Baxter R, Crane B, Aukes L, Wagner N, Fisher S, Jacobsen SJ, Sy L, Baggs J.
    Vaccine; 2011 Jul 12; 29(31):4891-6. PubMed ID: 21596088
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.